A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Inclusion Criteria: * Has HbA1c \>7.0% and \<=10.5% * Has a body mass index (BMI) \>=25 kg/m2 and \<=45 kg/m2 * Has received insulin glargine for 3 months prior to study start and has been on a stable dose for 1 month prior to study start * If taking oral antidiabetic agents, has been on a stable dose for at least 2 months Exclusion Criteria: * Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study) * Has received any investigational drug within 1 month of screening